• Component Description
• Eligible Sample
• Description of Laboratory Methodology
• Laboratory Method Files
• Laboratory Quality Assurance and Monitoring
• Data Processing and Editing
• Analytic Notes
• References
• Codebook
  • SEQN - Respondent Sequence Number
  • LBXSATSI - Alanine Aminotransferase (ALT) (U/L)
  • LBDSATLC - ALT Comment Code
  • LBXSAL - Albumin, refrigerated serum (g/dL)
  • LBDSALSI - Albumin, refrigerated serum (g/L)
  • LBXSAPSI - Alkaline Phosphatase (ALP) (IU/L)
  • LBXSASSI - Aspartate Aminotransferase (AST) (U/L)
  • LBXSC3SI - Bicarbonate (mmol/L)
  • LBXSBU - Blood Urea Nitrogen (mg/dL)
  • LBDSBUSI - Blood Urea Nitrogen (mmol/L)
  • LBXSCLSI - Chloride (mmol/L)
  • LBXSCK - Creatine Phosphokinase (CPK) (IU/L)
  • LBXSCR - Creatinine, refrigerated serum (mg/dL)
  • LBDSCRSI - Creatinine, refrigerated serum (umol/L)
  • LBXSGB - Globulin (g/dL)
  • LBDSGBSI - Globulin (g/L)
  • LBXSGL - Glucose, refrigerated serum (mg/dL)
  • LBDSGLSI - Glucose, refrigerated serum (mmol/L)
  • LBXSGTSI - Gamma Glutamyl Transferase (GGT) (IU/L)
  • LBDSGTLC - GGT Comment Code
  • LBXSIR - Iron, refrigerated serum (ug/dL)
  • LBDSIRSI - Iron, refrigerated serum (umol/L)
  • LBXSLDSI - Lactate Dehydrogenase (LDH) (IU/L)
  • LBXSOSSI - Osmolality (mmol/Kg)
  • LBXSPH - Phosphorus (mg/dL)
  • LBDSPHSI - Phosphorus (mmol/L)
  • LBXSKSI - Potassium (mmol/L)
  • LBXSNASI - Sodium (mmol/L)
  • LBXSTB - Total Bilirubin (mg/dL)
  • LBDSTBSI - Total Bilirubin (umol/L)
  • LBDSTBLC - Total Bilirubin Comment Code
  • LBXSCA - Total Calcium (mg/dL)
  • LBDSCASI - Total Calcium (mmol/L)
  • LBXSCH - Cholesterol, refrigerated serum (mg/dL)
  • LBDSCHSI - Cholesterol, refrigerated serum (mmol/L)
  • LBXSTP - Total Protein (g/dL)
  • LBDSTPSI - Total Protein (g/L)
  • LBXSTR - Triglycerides, refrig serum (mg/dL)
  • LBDSTRSI - Triglycerides, refrig serum (mmol/L)
  • LBXSUA - Uric acid (mg/dL)
  • LBDSUASI - Uric acid (umol/L)

National Health and Nutrition Examination Survey

2017-2018 Data Documentation, Codebook, and Frequencies

Standard Biochemistry Profile (BIOPRO_J)

Data File: BIOPRO_J.xpt

First Published: February 2020

Last Revised: NA

Component Description

These series of measurements are used in the diagnosis and treatment of certain liver, heart, and kidney diseases; acid-base imbalance in the respiratory and metabolic systems; other diseases involving lipid metabolism; various endocrine disorders; as well as other metabolic or nutritional disorders.

Alanine Aminotransferase (ALT)     

Alanine aminotransferase measurements are used in the diagnosis and treatment of certain liver diseases (e.g., viral hepatitis and cirrhosis) and heart diseases. Elevated levels of the transaminases can indicate myocardial infarction, hepatic disease, muscular dystrophy, or organ damage. Serum elevations of ALT activity are rarely observed, except in parenchymal liver disease, since ALT is a more liver-specific enzyme than aspartate aminotransferase (AST).

Albumin

Albumin measurements are used in the diagnosis and treatment of diseases involving the liver and/or kidneys, and are frequently used to assess nutritional status because plasma levels of albumin are dependent on protein intake.

Alkaline Phosphatase (ALP)

Alkaline phosphatase measurements are used in the diagnosis and treatment of liver, bone, and parathyroid disease.

Aspartate Aminotransferase (AST)

AST measurements are used in the diagnosis and treatment of certain types of liver and heart disease. Elevated levels of the transaminases can signal myocardial infarction, hepatic disease, muscular dystrophy, or organ damage.

Bicarbonate (HCO3)

Together with pH determination, bicarbonate measurements are used in the diagnosis and treatment of numerous potentially serious disorders associated with acid-base imbalance in the respiratory and metabolic systems.

Blood Urea Nitrogen (BUN)

BUN measurements are used in the diagnosis of certain renal and metabolic diseases. The determination of serum urea nitrogen is the most widely used test for the evaluation of kidney function. The test is frequently requested in conjunction with the serum creatinine test for the differential diagnosis of prerenal, renal, and post renal uremia. High BUN levels are associated with impaired renal function, increased protein catabolism, nephritis, intestinal obstruction, urinary obstruction, metallic poisoning, cardiac failure, peritonitis, dehydration, malignancy, pneumonia, surgical shock, Addison's disease, and uremia. Low BUN levels are associated with amyloidosis, acute liver disease, pregnancy, and nephrosis. Normal variations are observed according to a person's age and sex, the time of day, and their diet – particularly in their protein intake.       

Creatinine

Creatinine measurements are useful in the diagnosis and treatment of renal diseases.

Creatine Phosphokinase (CPK)

Measurements of creatine phosphokinase are used in the diagnosis and treatment of myocardial infarction, skeletal muscle diseases, and diseases of the central nervous system.

Gammaglutamyl Transaminase (GGT)

GGT measurements are principally used to diagnose and monitor hepatobiliary disease. It is currently the most sensitive enzymatic indicator of liver disease, with normal values rarely found in the presence of hepatic disease. It is also used as a sensitive screening test for occult alcoholism. Elevated levels are found in patients who chronically take drugs, such as phenobarbital and phenytoin.

Globulin

Globulins are a diverse group of proteins that transport various substances in the blood. They are also involved in various defense mechanisms within the body. Measurements of globulin are calculated (Total protein - Albumin), and are used to determine the serum globulin concentration.

Glucose

Glucose measurements are used in the diagnosis and treatment of pancreatic islet cell carcinoma and of carbohydrate metabolism disorders, including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia.         

Iron

Iron (non-heme) measurements are used in the diagnosis and treatment of diseases, such as iron deficiency anemia, chronic renal disease, and hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized   by pigmentation of the skin).

Lactate Dehydrogenase (LDH)

LDH measurements are used in the diagnosis and treatment of liver diseases, such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver; cardiac diseases, such as myocardial infarction; and tumors of the lungs or kidneys.

Osmolality

Serum osmolality is a measure of the number of dissolved particles in a solution, and is used to evaluate hydration status and detect potential toxins and foreign substances in the blood. (Osmolality is a calculated value on the chemistry analyzer: [(1.86*Na) + (GLUC/18) + (BUN/2.8) + 9].

Phosphorus

There is a reciprocal relationship between serum calcium and inorganic phosphorus. Any increase in the       level of inorganic phosphorus causes a decrease in the calcium level by a mechanism not clearly understood. Hyperphosphatemia is associated with vitamin D hypervitaminosis, hypoparathyroidism,     and renal failure. Hypophosphatemia is associated with rickets, hyperparathyroidism, and Fanconi syndrome.

Measurements of inorganic phosphorus are used in the diagnosis and treatment of various disorders, including parathyroid gland, kidney diseases, and vitamin D imbalance.

Potassium, Chloride, and Sodium

Hypokalemia (low serum potassium level) is associated with body potassium deficiency, excessive potassium loss caused by prolonged diarrhea or prolonged periods of vomiting and increased secretion of mineralocorticosteroids. Hyperkalemia (increased serum potassium level) is associated with oliguria, anuria, and urinary obstruction.
           
Low serum chloride values are associated with salt-losing nephritis; Addisonian crisis, prolonged vomiting, and metabolic acidosis caused by excessive production or diminished excretion of acids. High serum chloride values are associated with dehydration and conditions causing decreased renal blood flow, such as congestive heart failure.

Sodium measurements are used in the diagnosis and treatment of diseases involving electrolyte imbalance.

Total Bilirubin

Elevated levels are associated with hemolytic jaundice, paroxysmal hemoglobinuria, pernicious anemia, polycythemia, icterus neonatorum, internal hemorrhage, acute hemolytic anemia, malaria, and septicemia.

Low bilirubin levels are associated with aplastic anemia, and certain types of secondary anemia resulting from toxic therapy for carcinoma and chronic nephritis.

Total Calcium

Calcium measurements are used in the diagnosis and treatment of parathyroid disease, bone diseases, chronic renal disease and tetany. Urinary calcium measurement is used in the differential diagnosis of hypercalciuria.

Total Cholesterol

An elevated cholesterol level is associated with diabetes, nephrosis, hypothyroidism, biliary obstruction, and those rare cases of idiopathic hypercholesterolemia and hyperlipidemia; low levels are associated with hyperthyroidism, hepatitis, and sometimes severe anemia or infection.

Total Protein

Total protein measurements are used in the diagnosis and treatment of a variety of diseases involving the liver, kidney, or bone marrow, as well as other metabolic or nutritional disorders.

Triglycerides

Triglyceride measurements are used in the diagnosis of diabetes mellitus, nephrosis, liver obstruction, and other diseases involving lipid metabolism and various endocrine disorders and in the treatment of patients with these diseases.

Uric Acid

Uric acid measurements are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation, or other wasting conditions and in the treatment of patients receiving cytotoxic drugs.

Eligible Sample

Examined participants aged 12 years and older were eligible.

Description of Laboratory Methodology

NOTE: Glucose, cholesterol, and triglyceride were analyzed 1) as part of the biochemistry profile in this dataset; and 2) at other institutions, which are considered the reference methods for these measures. The results in this dataset do not replace the reference method data. See Analytical Notes section below for more detailed information.

All methods were measured on the Roche Cobas 6000 (c501 module) analyzer. See Laboratory Method Files for more detailed information about analyte methodologies, principles and operating procedures.

Alanine Aminotransferase (ALT)

The method to measure alanine aminotransferase (ALT) catalyzes the reaction of alpha-ketoglutarate with L-alanine to form L-glutamate and pyruvate. Under the action of LDH, pyruvate converts to lactate, and NADH is converted to NAD. The decrease in absorbance of NADH, measured at 340 nm (secondary wavelength is 700 nm), is directly proportional to the serum activity of ALT. It is a kinetic rate reaction.

Albumin

The method to measure albumin concentration utilizes the dye bromcresol purple (BCP). When the dye binds selectively with albumin in a pH range of 5.2-6.8, a color change occurs that is measured at 600 nm.  The secondary wavelength is 700 nm. This is a 2-point, endpoint reaction that is specific for albumin.

Aspartate Aminotransferase (AST)

Aspartate aminotransferase (AST) activity is determined by a modification of the method recommended by the International Federation of Clinical Chemistry (IFCC). AST catalyzes the reaction of alpha-ketoglutarate with L-aspartate to form L-glutamate and oxaloacetate. Under the action of malate dehydrogenase (MDH), oxaloacetate converts to malate, and NADH is oxidized to NAD. The decrease in absorbance of NADH, measured at 340 nm (secondary wavelength = 700 nm), is directly proportional to the serum activity of AST. It is a kinetic rate reaction.

Alkaline Phosphatase (ALP)

The method to measure alkaline phosphatase (ALP) utilizes a simple reaction wherein ALP acts upon a substrate (p-nitrophenol phosphate, or PNPP) in the presence of magnesium and zinc activators to form a colored product (p-nitrophenol) whose appearance is measured at 450 nm. The rate of p-nitrophenol formation is directly related to the amount of alkaline phosphatase in the specimen.

Bicarbonate (HCO₃)

The method to measure bicarbonate (HCO₃) utilizes an enzyme-based reaction. Phosphoenolpyruvate (PEP) is added to the specimen containing bicarbonate. Under the action of phosphoenolpyruvate carboxylase (PEPC) the PEP accepts the bicarbonate and is converted to oxaloacetate.  Then under the action of malate dehydrogenase, and in the presence of an NADH analog, the oxaloacetate is converted to malate, with the NADH analog converting to an NAD analog. The rate of disappearance of NADH analog is measured at 415 nm, and it is directly proportional to the amount of bicarbonate in the specimen.

Blood Urea Nitrogen (BUN)

The method to measure blood urea nitrogen utilizes a coupled enzyme reaction (urease, followed by glutamate dehydrogenase), with measurement of NADH (converting to NAD+) occurring at 340 nm.

Creatine Phosphokinase (CPK)

The method to measure creatine phosphokinase (CPK) or creatine kinase (CK) utilizes a coupled enzyme reaction. Creatine phosphate and adenosine diphosphate (ADP) are acted upon by CK in the serum specimen. Creatine and ATP are produced from this reaction, and ATP reacts with glucose under the action of hexokinase to produce glucose-6-phosphate and ADP. The glucose-6-phosphate reacts with NADP under the action of glucose-6-phosphate dehydrogenase to produce NADPH and a by-product. The photometrically (340 nm) measured rate of NADPH formation is directly proportional to the CK activity in the specimen.

Creatinine

Creatinine is measured using an enzymatic method in which creatinine is converted to creatine under the activity of creatininase. Creatine is then acted upon by creatinase to form sarcosine and urea. Sarcosine oxidase converts sarcosine to glycine and hydrogen peroxide, and the hydrogen peroxide reacts with a chromophore in the presence of peroxidase to produce a colored product that is measured at 546 nm (secondary wavelength = 700 nm). This is an endpoint reaction that agrees well with recognized HPLC methods, and it has the advantage over Jaffe picric acid-based methods that are susceptible to interferences from non-creatinine chromogens.

Gamma-glutamyl Transaminase (GGT)

The method to measure gamma-glutamyl transaminase (GGT) is a slight modification (slightly different substrate) of the method introduced by Szasz in 1969 (Whitfield JB, et. al., 1972) In the presence of glycylglycine, L-gamma-glutamyl-3-carboxy-4-nitroanilide is converted by GGT to 5-amino-2-nitrobenzoate and L-gamma-glutamyl-glycylglycine. The rate of colored product formation is directly related to the amount of GGT in the specimen, and the rate of its appearance is measured at 415 nm (secondary wavelength 700 nm). This is a kinetic (Rate-A) reaction.

Glucose

The method to measure glucose utilizes an enzymatic method that converts glucose to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose.

Iron

The Roche method of iron measurement is a three-step process using FerroZine reagent: Fe3+ is liberated from transferrin by acid/detergent, Fe3+ is reduced to Fe2+ by ascorbate, and the reduced iron then reacts with the FerroZine reagent to form a colored complex. The intensity of this final product is directly proportional to the iron concentration in the specimen.

Lactate Dehydrogenase (LDH)

The Roche method of LDH measurement is derived from the formulation recommended by the International Federation of Clinical Chemistry (IFCC) and is optimized for performance and stability. In the presence of cofactor NAD+, LDH converts L-lactate to pyruvate. NAD+ is reduced to NADH during this reaction. The initial rate of NADH formation is directly proportional to the catalytic LDH activity and is determined by measuring the increase in absorbance at 340 nm. This is a kinetic (Rate-A) reaction.

Phosphorus

The method used to measure phosphorus utilizes ammonium molybdate as the color-forming reagent. Measurement of the final product occurs at 340 nm (secondary wavelength 700 nm). Inorganic phosphate forms an ammonium phosphomolybdate complex having the formula (NH4)3[PO4(MoO3)12] with ammonium molybdate in the presence of sulfuric acid. The concentration of phosphomolybdate formed is directly proportional to the inorganic phosphate concentration.

Potassium, Chloride, & Sodium

An Ion-Selective Electrode (ISE) makes use of the unique properties of certain membrane materials to develop an electrical potential (electromotive force, EMF) for the measurements of ions in solution. The electrode has a selective membrane in contact with both the test solution and an internal filling solution. The internal filling solution contains the test ion at a fixed concentration. Because of the particular nature of the membrane, the test ions will closely associate with the membrane on each side. The membrane EMF is determined by the difference in concentration of the test ion in the test solution and the internal filling solution. The complete measurement system for a particular ion includes the ISE, a reference electrode and electronic circuits to measure and process the EMF to give the test ion concentration. The sodium and potassium electrodes are based on neutral carriers and the chloride electrode is based on an ion exchanger.

Chloride is measured using an indirect (specimen is diluted (1:31) by the instrument prior to analysis) ion-selective electrode (ISE) method for determination of the serum electrolyte concentrations.

Potassium ion concentration is measured by electrolyte activity in solution. This method utilizes an indirect (specimen is diluted by the instrument prior to analysis) ion-selective electrode (ISE) method for determination of the serum electrolyte concentrations.

Sodium is measured by the Roche Cobas 6000 (c501 module) system by utilizing indirect (or diluted) I.S.E. (ion selective electrode) methodology. This method utilizes an indirect (specimen is diluted by the instrument prior to analysis) ion-selective electrode (ISE) method for determination of the serum electrolyte concentrations.

Total Bilirubin

The method to measure total bilirubin is coupled with 3,5-dichlorophenyl diazonium in the presence of a solubilizing agent in a strongly acidic medium. The intensity of the red azo dye formed is directly proportional to the total bilirubin and can be determined photometrically (546 nm).

Total Calcium

The method used to measure total calcium reacts with 5-nitro-5’methyl-BAPTA (NM-BAPTA) under alkaline conditions to form a complex. This complex then reacts with EDTA to form a colored product whose intensity is directly proportional to the concentration of calcium in the specimen. It is measured photometrically at 340 nm.

Total Cholesterol

The method used to measure cholesterol is an enzymatic method where esterified cholesterol is converted to cholesterol by cholesterol esterase. The resulting cholesterol is then acted upon by cholesterol oxidase to produce cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide then reacts with 4-aminophenazone in the presence of peroxidase to produce a colored product that is measured at 505 nm (secondary wavelength = 700 nm). The final step is known as the Trinder reaction. This method is a single reagent, endpoint reaction that is specific for cholesterol.

Total Protein

The total protein method utilizes the biuret reaction with measurement of the final product at 546 nm. Divalent copper reacts in alkaline solution with protein peptide bonds to form the characteristic purple-colored biuret complex. Sodium potassium tartrate prevents the precipitation of copper hydroxide and potassium iodide prevents auto-reduction of copper. The color intensity is directly proportional to the protein concentration.

Triglycerides

The method used to measure triglyceride is based on the work by Wahlefeld using a lipoprotein lipase from microorganisms for the rapid and complete hydrolysis of triglycerides to glycerol followed by oxidation to dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide produced then reacts with 4-aminophenazone and 4-chlorophenol under the catalytic action of peroxidase to form a red dyestuff (Trinder endpoint reaction). The color intensity of the red dyestuff formed is directly proportional to the triglyceride concentration and can be measured photometrically.

Uric Acid

In this method uric acid is oxidized by uricase. Then the peroxide produced from this reaction is acted upon by peroxidase in the presence of 4 aminophenazone to produce a measurable colored product. It is a two-point, endpoint reaction, with measurement occurring at 546 nm (secondary wavelength 700 nm).

Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used.

There were changes to the lab equipment and lab site for this component in the NHANES 2017-2018 cycle. In the 2015-2016 cycle, analytes were measured on the Beckman Coulter UniCel DxC 800 Synchron and the Beckman Coulter UniCel DxC 660i Synchron Access chemistry analyzers at the Collaborative Laboratory Services in Ottumwa, IA. However, many of the methods in the NHANES 2017-2018 cycle are based on the same principles used in the 2015-2016 cycle.

Laboratory Method Files

BIOPRO - Alanine Amino Transferase (ALT) (February 2020)

BIOPRO - Albumin (February 2020)

BIOPRO - Alkaline Phosphatase (ALP) (February 2020)

BIOPRO - Aspartate Aminotransferase (AST) (February 2020)

BIOPRO - Bicarbonate (HCO3) (February 2020)

BIOPRO - Blood Urea Nitrogen (BUN) (February 2020)

BIOPRO - Chloride (February 2020)

BIOPRO - Creatine Phosphokinase (CPK) (February 2020)

BIOPRO - Creatinine (February 2020)

BIOPRO - Glucose - Serum - Refrigerated (February 2020)

BIOPRO - Gamma-Glutamyl Transferase (GGT) (February 2020)

BIOPRO - Iron - Refrigerated (February 2020)

BIOPRO - Lactate Dehydrogenase (LDH) (February 2020)

BIOPRO - Phosphorus (February 2020)

BIOPRO - Potassium (February 2020)

BIOPRO - Sodium (February 2020)

BIOPRO - Total Bilirubin (February 2020)

BIOPRO - Total Calcium (February 2020)

BIOPRO - Total Cholesterol - Refrigerated (February 2020)

BIOPRO - Total Protein (February 2020)

BIOPRO - Triglycerides - Refrigerated (February 2020)

BIOPRO - Uric Acid (February 2020)

Laboratory Quality Assurance and Monitoring

Serum specimens are processed, stored, and shipped to the University of Minnesota – Advanced Research Diagnostics Laboratory (ARDL), Minneapolis, MN for analysis.

Detailed instructions on specimen collection and processing are discussed in the NHANES Laboratory Procedures Manual (LPM). Vials are stored under appropriate refrigerated (2-8°C) conditions until they are shipped to Collaborative Laboratory Services for testing.

The NHANES quality control and quality assurance protocols (QA/QC) meet the 1988 Clinical Laboratory Improvement Act mandates. Detailed QA/QC instructions are discussed in the NHANES LPM.

Mobile Examination Centers (MECs)

Laboratory team performance is monitored using several techniques. NCHS and contract consultants use a structured competency assessment evaluation during visits to evaluate both the quality of the laboratory work and the quality-control procedures. Each laboratory staff member is observed for equipment operation, specimen collection and preparation; testing procedures and constructive feedback are given to each staff member. Formal retraining sessions are conducted annually to ensure that required skill levels were maintained.

Analytical Laboratories

NHANES uses several methods to monitor the quality of the analyses performed by the contract laboratories. In the MEC, these methods include performing blind split specimens collected during “dry run” sessions. In addition, contract laboratories randomly perform repeat testing on 2% of all specimens.

NCHS developed and distributed a quality control protocol for all CDC and contract laboratories, which outlined the use of Westgard rules (Westgard, et al. 1981) when running NHANES specimens. Progress reports containing any problems encountered during shipping or receipt of specimens, summary statistics for each control pool, QC graphs, instrument calibration, reagents, and any special considerations are submitted to NCHS quarterly. The reports are reviewed for trends or shifts in the data. The laboratories are required to explain any identified areas of concern.

Data Processing and Editing

The data were reviewed. Incomplete data or improbable values were sent to the performing laboratory for confirmation.

There were 13 additional variables created in this data file to convert the analyzed values into International System of Units (SI). These variables were created using the following formulas:

LBXSAL conversion to LBDSALSI

Albumin in g/dL (LBXSAL) was converted to g/L (LBDSALSI) by multiplying by 10

LBXSBU conversion to LBDSBUSI

Blood urea nitrogen (BUN) in mg/dL (LBXSBU) was converted to mmol/L (LBDSBUSI) by multiplying by 0.357

LBXSCA conversion to LBDSCASI

Calcium in mg/dL (LBXSCA) was converted to mmol/L (LBDSCASI) by multiplying by 0.250

LBXSCH conversion to LBDSCHSI

Cholesterol in mg/dL (LBXSCH) was converted to mmol/L (LBDSCHSI) by multiplying by 0.0259

LBXSCR conversion to LBDSCRSI

Creatinine in mg/dL (LBXSCR) was converted to µmol/L (LBDSCRSI) by multiplying by 88.4

LBXSGL conversion to LBDSGLSI

Glucose in mg/dL (LBXSGL) was converted to mmol/L (LBDSGLSI) by multiplying by 0.0555

LBXSIR conversion to LBDSIRSI

Iron in µg/dL (LBXSIR) was converted to µmol/L (LBDSIRSI) by multiplying by 0.1791

LBXSPH conversion to LBDSPHSI

Phosphorus in mg/dL (LBXSPH) was converted to mmol/L (LBDSPHSI) by multiplying by 0.323

LBXSTB conversion to LBDSTBSI

Total bilirubin in mg/dL (LBXSTB) was converted to µmol/L (LBDSTBSI) by multiplying by 17.1

LBXSTP conversion to LBDSTPSI

Total protein in g/dL (LBXSTP) was converted to g/L (LBDSTPSI) by multiplying by 10

LBXSTR conversion to LBDSTRSI

Triglycerides in mg/dL (LBXSTR) were converted to mmol/L (LBDSTRSI) by multiplying by 0.0113

LBXSTR conversion to LBDSTRSI

Uric acid in mg/dL (LBXSUA) was converted to µmol/L (LBDSUASI) by multiplying by 59.48

LBXSGB conversion to LBDSGBSI

Globulin in g/dL (LBXSGB) was converted to g/L (LBDSGBSI) by multiplying by 10

Analytic Notes

Refer to the 2017-2018 Laboratory Data Overview for general information on NHANES laboratory data.

There are over 800 laboratory tests performed on NHANES participants. However, not all participants provided biospecimens or enough volume for all the tests to be performed. The specimen availability can also vary by age or other population characteristics. For example, in 2017-2018, approximately 80% of children aged 1-17 years who were examined in the MEC provided a blood specimen through phlebotomy, while 95% of examined adults age 18 and older provided a blood specimen. Analysts should evaluate the extent of missing data in the dataset related to the outcome of interest as well as any predictor variables used in the analyses to determine whether additional re-weighting for item non-response is necessary.

Please refer to the NHANES Analytic Guidelines and the on-line NHANES Tutorial for further details on the use of sample weights and other analytic issues.

Demographic and Other Related Variables

The analysis of NHANES laboratory data must be conducted using the appropriate survey design and demographic variables. The NHANES 2017-2018 Demographics File contains demographic data, health indicators, and other related information collected during household interviews as well as the sample design variables. The recommended procedure for variance estimation requires use of stratum and PSU variables (SDMVSTRA and SDMVPSU, respectively) in the demographic data file. 

The Fasting Questionnaire File includes auxiliary information, such as fasting status, length of fast and the time of venipuncture.

This laboratory data file can be linked to the other NHANES data files using the unique survey participant identifier (i.e., SEQN).

Glucose (LBXSGL)

This glucose value was obtained from the standard battery of biochemical assessments. Use of the laboratory test result from the reference method (LBXGLU), rather than the standard battery of biochemical assessments value (LBXSGL), is generally recommended. These serum glucose values (LBXSGL) reported in this data file should not be used to determine undiagnosed diabetes or prediabetes. Instead, plasma glucose values (LBXGLU) should be used, which are based on the reference analytic method in the GLU_J data file. Special weights included in the GLU_J data file should be used when analyzing these data.

Total Cholesterol (LBXSCH)

This total cholesterol value was obtained from the standard battery of biochemical assessments. Use of the laboratory test result from the reference method (LBXTC), rather than the standard battery of biochemical assessments value (LBXSCH), is generally recommended. For most serum cholesterol analyses, the appropriate variable to use will be (LBXTC) in the TCHOL_J data file. The (LBXSCH) value from the standard biochemistry profile should not be used routinely.

Triglycerides (LBXSTR)

This triglyceride value was obtained from the standard battery of biochemical assessments. Use of the laboratory test result from the reference method (LBXTR), rather than the standard battery of biochemical assessments value (LBXSTR), is generally recommended. For most triglyceride analyses, the appropriate variable to use is (LBXTR) in the TRIGLY_J data file. The value from the standard biochemistry profile (LBXSTR) should not be used routinely.

Detection Limits

The detection limits were constant for all of the analytes in the data set.

The lower limit of detection (LLOD) for the Standard Biochemistry Profile:

*Incompatible with human life

Standard Biochemistry Profile regression equations to compare 2017-2018 and 2015-2016 data:

Method validation (bridging) studies were performed to compare results from a laboratory, instrument, and method change between the 2015-2016 and 2017-2018 survey cycles using NHANES samples from late 2016. During the 2015-2016 cycle the Beckman Coulter UniCel DxC 800 Synchron was upgraded to the Beckman Coulter UniCel DxC 660i Synchron Access chemistry analyzer (DxC 660i). Previous analyses indicated that no statistical adjustment is needed for results obtained between the two Beckman UniCel® analyzers (i.e., DxC 800 and DxC 660i). During the 2017-2018 cycle the Roche Cobas 6000 chemistry analyzer (Cobas 6000) was used for the entire 2017-2018 cycle. Analyses comparing results obtained from the Cobas 6000 to those obtained from the DxC 660i using selected serum samples (n=248) from NHANES participants in 2016 indicate that adjustments are needed for some analytes as described below.

The table below provides a list of the standard biochemistry profile analytes and results from the bridging study for each analyte. It includes mean differences (% Diff), correlation coefficients (r), and when recommended the regression model used for the adjustment as well as the forward and backward adjustment equations. When differences between the two measurements were proportional to concentration, Weighted Deming regressions were chosen to adjust the results. When differences were constant across the interval of concentration, a non-weighted Deming regression was chosen. A Log Deming regression was used to adjust an analyte whose measurements were heavily skewed to the right. All analyses were performed using Analyse-it, v4.30.4.

It is recommended that these equations be used when examining trends among standard biochemistry profile data across 1999-2016 and 2017-2018 cycles, or when combining 2017-2018 data with previous cycles. For more detailed information on the standard biochemistry profile data files in the previous cycles, please refer to the documentations accompanying these datasets.

VARIABLE NAME (unit)	STATISTICAL ADJUSTMENT METHOD	FORWARD EQUATIONS [CI]	BACKWARD EQUATIONS [CI]	% DIFF	r
LBXSAL (g/dL)	Non-weighted Deming	X (Cobas 6000) = 0.9581 [95%CI: 0.9282 to 0.9881] * Y (DxC 660i) - 0.0108 [95%CI: -0.1413 to 0.1197]	X (DxC 660i) = 1.044 [95%CI: 1.011 to 1.076] * Y (Cobas 6000) + 0.01128 [95%CI: -0.1247 to 0.1473]	-4.42	0.968
LBXSAPSI (U/L)	Log Deming Regression	Log10  X (Cobas 6000) = 0.9986 [95% CI: 0.9915 to 1.006] * Log10 Y (DxC 660i) + 0.04288 [95% CI: 0.02936 to 0.05640]	Log10 X (DxC 660i) = 1.001 [95%CI: 0.9943 to 1.009] * Log10 Y (Cobas 6000) - 0.04294 [95%CI: -0.05678 to -0.02911]	9.74	1
LBXSASSI (U/L)	Non-weighted Deming	X (Cobas 6000) = 0.9822 [95% CI: 0.9673 to 0.9970] * Y (DxC 660i) - 3.695 [95% CI: -4.093 to -3.298]	X (DxC 660i) = 1.018 [95%CI: 1.003 to 1.034] * Y (Cobas 6000) + 3.762 [95%CI: 3.409 to 4.115]	-18.03	0.99
LBXSATSI (U/L)	Non-weighted Deming	X (Cobas 6000) = 0.9869 [95% CI: 0.9762 to 0.9976] * Y (DxC 660i) - 2.653 [95% CI: -2.919 to -2.387]	X (DxC 660i) = 1.013 [95%CI: 1.002 to 1.024] * Y (Cobas 6000) + 2.688 [95%CI: 2.443 to 2.934]	-15.46	0.997
LBXSBU (g/dL)	Non-weighted Deming	X (Cobas 6000) = 0.9992 [95% CI: 0.9827 to 1.016] * Y (DxC 660i) - 0.4484 [95% CI: -0.6835 to -0.2134]	X (DxC 660i) = 1.001 [95%CI: 0.9843 to 1.017] * Y (Cobas 6000) + 0.4488 [95%CI: 0.2207 to 0.6768]	-3.36	0.992
LBXSC3SI (mmol/L)	Adjustment Not Recommended	N/A	N/A	1.74	0.749
LBXSCA (mg/dL)	Adjustment Not Recommended	N/A	N/A	-2.12	0.892
LBXSCH (mg/dL)	Weighted Deming	X (Cobas 6000) = 0.9556 [95% CI: 0.9419 to 0.9693] * Y (DxC 660i) + 2.105 [95% CI: -0.1178 to 4.328]	X (DxC 660i) = 1.046 [95%CI: 1.031 to 1.062] * Y (Cobas 6000) - 2.203 [95%CI: -4.560 to 0.1550]	-3.21	0.99
LBXSCK1  (IU/L)	Weighted Deming	X (Cobas 6000) = 1.068 [95% CI: 1.062 to 1.075] * Y (DxC 660i) - 1.131 [95% CI: -1.906 to -0.3569]	X (DxC 660i) = 0.9360 [95%CI: 0.9303 to 0.9416] * Y (Cobas 6000) + 1.059 [95%CI: 0.3399 to 1.778]	5.91	1
LBXSCLSI (IU/L)	Adjustment Not Recommended	N/A	N/A	-1.44	0.756
LBXSCR (mg/dL)	Non-weighted Deming	X (Cobas 6000) = 0.9515 [95% CI: 0.9365 to 0.9665] * Y (DxC 660i) + 0.06608 [95% CI: 0.05252 to 0.07963]	X (DxC 660i) = 1.051 [95%CI: 1.034 to 1.068] * Y (Cobas 6000) - 0.06945 [95%CI: -0.08474 to -0.05415]	3.354	0.993
LBXSGB (g/dL)	CALCULATED	N/A	N/A	N/A	N/A
LBXSGL (mg/dL)	Adjustment Not Recommended	N/A	N/A	2.41	0.999
LBXSGTSI (U/L)	Weighted Deming	X (Cobas 6000) = 1.243 [95% CI: 1.223 to 1.263] * Y (DxC 660i) - 2.938 [95% CI: -3.352 to -2.524]	X (DxC 660i) = 0.8042 [95%CI: 0.7913 to 0.8172] * Y (Cobas 6000) + 2.363 [95%CI: 2.066 to 2.660]	7.7	0.999
LBXSIR (ug/dL)	Non-weighted Deming	X (Cobas 6000) = 1.023 [95% CI: 1.013 to 1.033] * Y (DxC 660i) + 4.597 [95% CI: 3.839 to 5.354]	X (DxC 660i) = 0.9776 [95%CI: 0.9678 to 0.9873] * Y (Cobas 6000) - 4.494 [95%CI: -5.275 to -3.712]	10.01	0.998
LBXSKSI (mmol/L)	Adjustment Not Recommended	N/A	N/A	-1.398	0.970
LBXSLDSI (U/L)	Weighted Deming	X (Cobas 6000) = 1.167 [95% CI: 1.141 to 1.194] * Y (DxC 660i) - 2.407 [95% CI: -5.758 to 0.9439]	X (DxC 660i) = 0.8568 [95%CI: 0.8373 to 0.8762] * Y (Cobas 6000) + 2.062 [95%CI: -0.7646 to 4.890]	14.86	0.987
LBXSNASI (mmol/L)	Adjustment Not Recommended	N/A	N/A	0.80	0.605
LBXSOSSI (mmol/Kg)	CALCULATED	N/A	N/A	N/A	N/A
LBXSPH (mg/dL)	Adjustment Not Recommended	N/A	N/A	-1.80	0.992
LBXSTB (mg/dL)	Adjustment Not Recommended	N/A	N/A	-3.19	0.938
LBXSTP (g/dL)	Adjustment Not Recommended	N/A	N/A	0.36	0.932
LBXSTR (mg/dL)	Non-weighted Deming	X (Cobas 6000) = 1.036 [95% CI: 0.9973 to 1.074] * Y (DxC 660i) + 7.271 [95% CI: 3.361 to 11.18]	X (DxC 660i) = 0.9655 [95%CI: 0.9293 to 1.002] * Y (Cobas 6000) - 7.020 [95%CI: -11.09 to -2.945]	13.44	0.997
LBXSUA (mg/dL)	Non-weighted Deming	X (Cobas 6000) = 1.073 [95% CI: 1.060 to 1.085] * Y (DxC 660i) - 0.2495 [95% CI: -0.3167 to -0.1823]	X (DxC 660i) = 0.9323 [95%CI: 0.9212 to 0.9435] * Y (Cobas 6000) + 0.2326 [95%CI: 0.1727 to 0.2925]	2.37	0.996

 

1. One of the data points was deemed an extreme outlier, therefore only data from 247 serum samples were used in the analysis for creatinine phosphokinase (LBXSCK).

References

• Anderson, S.C., Cockayne, S. Clinical Chemistry: Concepts and Applications. New York: McGraw-Hill, 2003. Print.
• Caudill S.P., Schleicher R.L., Pirkle J.L. Multi-rule quality control for the age-related eye disease study. Statist. Med. (2008) 27(20):4094-40106.
• Gennari, F.John. Serum Osmolality: Uses and Limitations. The New England Journal of Medicine [0028-4793]. 1984. 310:2:102 -105.
• Myers, GL et al. Recommendations for improving serum creatinine measurement: A report from the laboratory working group of the National Kidney Disease Education Program. Clin. Chem. 2006:5-18.
• Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, Levey AS et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis 2007; 50(6):918-926.
• Wahlefeld, August W. Triglycerides Determination after Enzymatic Hydrolysis. Methods of Enzymatic Analysis (2nd English Edition). 1974. 4:1831-1835.
• Weisberg HF. Unraveling the laboratory model of a syndrome: The osmolality model. In: Young DS, Hicks J, Nipper H, et al, eds. Clinician and Chemist. The Relationship of the Laboratory to the Physician. Washington, DC: American Association of Clinical Chemistry;1979:200-243.
• Westgard J.O., Barry P.L., Hunt M.R., Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem (1981) 27:493-501.
• Whitfield JB, Pounder RE, Neale G, et al. Serum γ-glutamyl transpeptidase activity in liver disease. Gut 1972;13:702-708.

Codebook and Frequencies